Today: 9 June 2026
Liberty Broadband stock jumps with Charter rally — what investors watch next week
1 February 2026
2 mins read

Liberty Broadband stock jumps with Charter rally — what investors watch next week

New York, Feb 1, 2026, 07:10 EST — The market has closed.

  • Liberty Broadband shares closed Friday up 7.7%, tracking Charter’s jump after its earnings report
  • Charter reported a slowdown in broadband losses, yet revenue declined and fell short of analyst expectations
  • Attention now turns to deal terms, the challenge from wireless broadband, and Liberty’s Q&A call set for Feb. 11

Shares of Liberty Broadband Corporation jumped 7.7% to close at $48.02 on Friday, following a 7.6% gain in Charter Communications. Investors seized on early signs that cable broadband churn could be leveling off. U.S. markets are closed Sunday and will reopen Monday.

This move is significant for Liberty Broadband because it effectively acts as a stand-in for Charter stock. In its annual report filed Friday, Charter disclosed that Liberty Broadband’s main assets include roughly 41.5 million shares of Charter Class A stock. Liberty shareholders are set to receive 0.236 of a Charter Class A share for each Liberty share once the pending deal closes. The filing also notes the transaction’s “outside date” is Aug. 31, 2027, with a side letter potentially moving the closing up to sync with Charter’s separate Cox deal. SEC

Charter, known for its Spectrum brand, reported a 2.3% drop in fourth-quarter revenue to $13.6 billion. Adjusted EBITDA slipped 1.2%, landing at $5.7 billion. The company lost 119,000 internet customers but gained 428,000 mobile lines. It projects capital spending around $11.4 billion for 2026. “Our focus in 2026 is to message our product utility, value and high-quality service to customers,” CEO Chris Winfrey said in the release. PR Newswire

Despite Friday’s rally, the debate lingers. Charter lost fewer internet customers than analysts predicted, but revenue still fell short. New Street Research’s Vikash Harlalka remarked, “We think it will be a while before we see a major improvement in Charter’s broadband subscriber trends.” Winfrey highlighted the wind-down of a long buildout, adding: “In 2026, we’ll nearly complete our rural build-out, providing us with over 1.7 million new subsidized rural passings.” Reuters

Competition is lurking in the background. Verizon posted its strongest quarterly wireless subscriber growth in six years, fueled by aggressive promotions, and followed up with a $25 billion share buyback plan. It also projected higher profit and free cash flow for 2026. This matters for cable because “fixed wireless” home internet—offered through mobile networks—has gained traction as a viable option for some households. Reuters

Liberty Broadband holders face a clear early test on Monday: will Charter’s rally stick once investors dig back into the quarter’s numbers? Liberty typically tracks Charter’s swings, with deal calculations and the implied exchange value lurking just beneath the surface.

Traders are also scanning for updates on the timing and regulatory risks tied to Charter’s planned Cox deal and the Liberty Broadband merger. Either could shift the spread between Liberty and Charter on any given session.

The downside is clear. Should broadband losses pick up again, or if wireless and fiber discounts deepen due to promotions, Charter’s cash flow could take a hit, and Liberty’s gains might evaporate fast. On the flip side, deal uncertainty works against the stock: a lengthy delay or regulatory hurdles could push the discount wider, even if Charter’s shares hold steady.

Liberty Broadband’s quarterly Q&A session is set for Wednesday, Feb. 11 at 11:15 a.m. ET, following prepared remarks on GCI Liberty’s fourth-quarter earnings call. Investors will probably zero in on the Charter stake and the timeline for any deals.

Stock Market Today

  • Rocket Lab Stock Price Forecast: AI Analyst Cautions Despite 60% Surge
    June 9, 2026, 10:12 AM EDT. Shares of Rocket Lab USA ($RKLB) have jumped more than 60% year-to-date due to increased demand for small-satellite launches. Despite the rally, AI-driven analysis from TipRanks highlights caution, urging investors to consider potential market volatility and competitive pressures. Rocket Lab's growth taps into expanding satellite deployment, but risks remain in a crowded aerospace sector. Investors should balance optimism with these cautionary signals from advanced analytics.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
SSE share price flat at 2,422p as a key trading update looms this week
Previous Story

SSE share price flat at 2,422p as a key trading update looms this week

Bitcoin price breaks below $80,000 after silver rout — and Warren Buffett’s Berkshire Hathaway sees American Express nearly catch Apple
Next Story

Bitcoin price breaks below $80,000 after silver rout — and Warren Buffett’s Berkshire Hathaway sees American Express nearly catch Apple

Go toTop